Tagged: Monitoring

Why Incrementalism Won’t Fix Clinical Development

A recent study by the UK’s Office of Health Economics shows no let-up in pharma’s efficiency crisis. OHE’s study sets the cost of R&D for a new medicine at $1.9 B. Discussions I’ve had this week with senior staff at several large pharma companies were a reminder of why efficiency remains a major issue for… Read more »